- Summary
- Actions
- Committee Votes
- Floor Votes
- Memo
- Text
- LFIN
- Chamber Video/Transcript
A07006 Summary:
BILL NO | A07006 |
  | |
SAME AS | SAME AS S05629 |
  | |
SPONSOR | Gottfried (MS) |
  | |
COSPNSR | Zebrowski, Ortiz, Mosley, Lavine, Hunter, Cook, Hevesi, D'Urso, Skoufis, Simon, Glick, McDonald, Miller ML, Sepulveda, Walter, Peoples-Stokes, Hooper, Galef, Richardson, Carroll, Blake, Lupardo, Brindisi, Steck, Raia, Wallace, Morelle, Abinanti, Wright, Kolb, Walker |
  | |
MLTSPNSR | Cahill, Dinowitz, Lentol, McDonough, Morinello, Rozic |
  | |
Amd §3360, Pub Health L | |
  | |
Includes post-traumatic stress disorder as a condition permitting the use of medical marihuana. |
A07006 Actions:
BILL NO | A07006 | |||||||||||||||||||||||||||||||||||||||||||||||||
  | ||||||||||||||||||||||||||||||||||||||||||||||||||
03/29/2017 | referred to health | |||||||||||||||||||||||||||||||||||||||||||||||||
04/25/2017 | reported | |||||||||||||||||||||||||||||||||||||||||||||||||
04/27/2017 | advanced to third reading cal.239 | |||||||||||||||||||||||||||||||||||||||||||||||||
05/02/2017 | passed assembly | |||||||||||||||||||||||||||||||||||||||||||||||||
05/02/2017 | delivered to senate | |||||||||||||||||||||||||||||||||||||||||||||||||
05/02/2017 | REFERRED TO HEALTH | |||||||||||||||||||||||||||||||||||||||||||||||||
06/20/2017 | SUBSTITUTED FOR S5629 | |||||||||||||||||||||||||||||||||||||||||||||||||
06/20/2017 | 3RD READING CAL.903 | |||||||||||||||||||||||||||||||||||||||||||||||||
06/20/2017 | PASSED SENATE | |||||||||||||||||||||||||||||||||||||||||||||||||
06/20/2017 | RETURNED TO ASSEMBLY | |||||||||||||||||||||||||||||||||||||||||||||||||
11/10/2017 | delivered to governor | |||||||||||||||||||||||||||||||||||||||||||||||||
11/11/2017 | signed chap.403 |
A07006 Committee Votes:
Gottfried | Aye | Raia | Aye | ||||||
Schimminger | Aye | McDonough | Aye | ||||||
Galef | Aye | Ra | Aye | ||||||
Dinowitz | Aye | Walter | Aye | ||||||
Cahill | Aye | Garbarino | Aye | ||||||
Paulin | Aye | Byrne | Aye | ||||||
Cymbrowitz | Aye | Norris | Aye | ||||||
Gunther | Aye | ||||||||
Rosenthal | Aye | ||||||||
Hevesi | Aye | ||||||||
Lavine | Aye | ||||||||
Titone | Aye | ||||||||
Mayer | Aye | ||||||||
Jaffee | Aye | ||||||||
Steck | Aye | ||||||||
Abinanti | Aye | ||||||||
Braunstein | Aye | ||||||||
Kim | Aye | ||||||||
Solages | Aye | ||||||||
Go to top
A07006 Floor Votes:
Yes
Abbate
Yes
Crouch
No
Goodell
Yes
Lifton
Yes
O'Donnell
Yes
Simanowitz
Yes
Abinanti
No
Curran
Yes
Gottfried
Yes
Lopez
Yes
Ortiz
Yes
Simon
Yes
Arroyo
Yes
Cusick
No
Graf
Yes
Lupardo
Yes
Otis
ER
Simotas
Yes
Aubry
Yes
Cymbrowitz
Yes
Gunther
ER
Lupinacci
ER
Palmesano
Yes
Skartados
Yes
Barclay
Yes
Davila
Yes
Harris
Yes
Magee
Yes
Palumbo
Yes
Skoufis
Yes
Barnwell
Yes
De La Rosa
No
Hawley
Yes
Magnarelli
Yes
Paulin
Yes
Solages
Yes
Barrett
Yes
DenDekker
ER
Hevesi
Yes
Malliotakis
ER
Peoples-Stokes
Yes
Stec
Yes
Barron
Yes
Dickens
Yes
Hikind
Yes
Mayer
Yes
Perry
Yes
Steck
Yes
Benedetto
Yes
Dilan
Yes
Hooper
Yes
McDonald
Yes
Pheffer Amato
ER
Stirpe
Yes
Bichotte
Yes
Dinowitz
Yes
Hunter
Yes
McDonough
Yes
Pichardo
Yes
Thiele
Yes
Blake
ER
DiPietro
Yes
Hyndman
Yes
McKevitt
Yes
Pretlow
Yes
Titone
Yes
Blankenbush
Yes
D'Urso
Yes
Jaffee
Yes
McLaughlin
Yes
Quart
Yes
Titus
No
Brabenec
Yes
Englebright
Yes
Jean-Pierre
Yes
Miller B
Yes
Ra
Yes
Vanel
Yes
Braunstein
Yes
Errigo
Yes
Jenne
Yes
Miller MG
Yes
Raia
Yes
Walker
Yes
Brindisi
Yes
Fahy
Yes
Johns
Yes
Miller ML
Yes
Ramos
Yes
Wallace
Yes
Bronson
Yes
Farrell
Yes
Jones
No
Montesano
Yes
Richardson
Yes
Walsh
Yes
Buchwald
ER
Finch
Yes
Joyner
Yes
Morelle
Yes
Rivera
Yes
Walter
Yes
Butler
No
Fitzpatrick
Yes
Kavanagh
Yes
Morinello
Yes
Rodriguez
Yes
Weinstein
Yes
Byrne
No
Friend
Yes
Kearns
Yes
Mosley
Yes
Rosenthal
Yes
Weprin
Yes
Cahill
Yes
Galef
Yes
Kim
Yes
Moya
Yes
Rozic
Yes
Williams
Yes
Carroll
ER
Gantt
Yes
Kolb
Yes
Murray
Yes
Ryan
Yes
Woerner
Yes
Castorina
Yes
Garbarino
Yes
Lalor
Yes
Niou
Yes
Santabarbara
Yes
Wright
Yes
Colton
ER
Giglio
Yes
Lavine
Yes
Nolan
Yes
Schimminger
Yes
Zebrowski
Yes
Cook
Yes
Gjonaj
Yes
Lawrence
Yes
Norris
Yes
Seawright
Yes
Mr. Speaker
Yes
Crespo
Yes
Glick
Yes
Lentol
Yes
Oaks
Yes
Sepulveda
‡ Indicates voting via videoconference
A07006 Memo:
Go to topNEW YORK STATE ASSEMBLY
MEMORANDUM IN SUPPORT OF LEGISLATION
submitted in accordance with Assembly Rule III, Sec 1(f)   BILL NUMBER: A7006 SPONSOR: Gottfried (MS)
  TITLE OF BILL: An act to amend the public health law, in relation to conditions permitting the use of medical marihuana   PURPOSE OR GENERAL IDEA OF BILL: This bill would make post-traumatic stress disorder (PTSD) an eligible condition under the state medical marijuana law.   SUMMARY OF PROVISIONS: Section 1 of this bill amends section 3360 of the Public Health Law, to add post traumatic stress disorder to the list of conditions for which medical marijuana may be used. Section 2 of this bill provides that this act shall take effect imme- diately.   EXISTING LAW: The Public Health Law specifies ten medical conditions that are eligible for use of medical marijuana and chronic pain has been added by action of the Health Commissioner. PTSD is not among those conditions.   JUSTIFICATION: Post-traumatic stress disorder (PTSD), first defined in 1980, is a seri- ous condition that involves a person developing symptoms - such as anger, flashbacks, nightmares, night sweats, numbing, insomnia, and avoidance - after experiencing a traumatic stressor. Many patients find the available pharmaceutical options dangerous or ineffective, and thou- sands of them have turned to medical marijuana for relief. States are increasingly adding PTSD to their lists of qualifying conditions for medical marijuana. PTSD afflicts numerous patient groups. While the public typically asso- ciates PTSD with military veterans, PTSD is also found among survivors of domestic violence, rape, violent crime, accidents, and among police and fire fighters. Women are twice as likely as men to experience PTSD. PTSD results from an endocannabinoid deficiency. The endocannabinoid system is part of the brain and nervous system involved with appetite, pain-sensation, mood, and memory. With PTSD, the body stops producing enough endocannabinoids to fill receptor sites. This is where the canna- binoids found in marijuana play a therapeutic role. Of the 28 states with medical marijuana programs, 23 cover patients with PTSD. Six of those states collect patient use data. Extrapolating from the relative number of PTSD patients in those six states, approximately 19,000 patients with PTSD in New York could benefit from the use of medical marijuana. Some argue that treatment of PTSD with medical marijuana is not based on double-blind clinical studies proving its efficacy. However, most of the drugs commonly used to treat PTSD also lack clinical proof of their efficacy. Only two drugs have been approved by the FDA for the treatment of PTSD: sertraline (Zoloft), and paroxetine (Paxil). Unlike medical marijuana, both of these drugs have serious side effects, including the risk of suicide, weight gain, and the onset of diabetes. Every other drug used in the treatment of PTSD is prescribed "off label," which means they were not approved by the FDA for the treatment of PTSD. Many of these drugs, which include benzodiazepines, antipsychotics, and mood stabilizers, are even more dangerous and addictive than Zoloft and Paxil. Indeed, the Army Surgeon General issued a warning against the use of antipsychotics for veterans with PTSD in 2012. While available research about medical marijuana for PTSD is limited-be- cause of federal obstacles to conducting such research-the research that does exist supports the use. For example, a Canadian study involving naboline - a prescription drug made of a synthetic cannabinoid (compo- nent of marijuana) reported that, "The majority of patients (72%) receiving naboline experienced either cessation of nightmares or a significant reduction in nightmare intensity. Subjective improvement in sleep time, the quality of sleep, and the reduction of day-time flash- backs and nightsweats were also noted by some patients." In New Mexico, a 2014 study of 80 patients who administered medical marijuana for PTSD, pursuant to state law, found "greater than 75% reduction in CAPS (Clinician Administered Post-traumatic Scale) symptom scores were reported when patients were using cannabis than when they were not... There is extensive evidence that cannabinoids may facilitate extinction of aversive memories." They also found a 77% reduction in suicidal thoughts, and a 50% reduction in the use of medications. The New Mexico study also reported that not a single adverse event occurred among over 3,350 patients with PTSD using medical marijuana that they were tracking.   PRIOR LEGISLATIVE HISTORY: New bill.   FISCAL IMPLICATIONS: The State of New York and certain counties will realize additional tax revenue from the sale of medical marijuana to patients with PTSD.   EFFECTIVE DATE: Immediately
A07006 Text:
Go to top STATE OF NEW YORK ________________________________________________________________________ 7006 2017-2018 Regular Sessions IN ASSEMBLY March 29, 2017 ___________ Introduced by M. of A. GOTTFRIED, KEARNS, ZEBROWSKI, ORTIZ, MOSLEY, LAVINE, HUNTER, COOK, HEVESI, D'URSO, SKOUFIS, SIMON, GLICK, McDONALD, M. L. MILLER, SEPULVEDA, WALTER, PEOPLES-STOKES, HOOPER, GALEF, RICH- ARDSON, MOYA, CARROLL, BLAKE, LUPARDO, BRINDISI -- Multi-Sponsored by -- M. of A. CAHILL, DINOWITZ, FARRELL, LENTOL, McDONOUGH, McLAUGHLIN, MORINELLO, ROZIC -- read once and referred to the Committee on Health AN ACT to amend the public health law, in relation to conditions permit- ting the use of medical marihuana The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Paragraph (a) of subdivision 7 of section 3360 of the 2 public health law, as added by chapter 90 of the laws of 2014, is 3 amended to read as follows: 4 (a) "Serious condition" means: 5 (i) having one of the following severe debilitating or life-threaten- 6 ing conditions: cancer, positive status for human immunodeficiency virus 7 or acquired immune deficiency syndrome, amyotrophic lateral sclerosis, 8 Parkinson's disease, multiple sclerosis, damage to the nervous tissue of 9 the spinal cord with objective neurological indication of intractable 10 spasticity, epilepsy, inflammatory bowel disease, neuropathies, 11 Huntington's disease, post-traumatic stress disorder, or as added by the 12 commissioner; and 13 (ii) any of the following conditions where it is clinically associated 14 with, or a complication of, a condition under this paragraph or its 15 treatment: cachexia or wasting syndrome; severe or chronic pain; severe 16 nausea; seizures; severe or persistent muscle spasms; or such conditions 17 as are added by the commissioner. 18 § 2. This act shall take effect immediately; provided that the amend- 19 ments to title 5-A of article 33 of the public health law made by 20 section one of this act shall not affect the repeal of such title and 21 shall be deemed repealed therewith. EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD10804-01-7